BCRX
BioCrystBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-22
Current thesis
The bull case is that BioCryst has moved from a single-product commercialization story toward a broader HAE platform: 2025 ORLADEYO revenue reached $601.8 million, 2026 ORLADEYO guidance was maintained at $625 million to $645 million, profitability improved, pediatric expansion added reach, and navenibart gives the company a potentially differentiated long-acting prophylaxis asset. [#8-K-2026-02-26] [#10-K-2026-02-26]
Posture
Constructive
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta -0.1.
What can break
BCX17725 is still an early Phase 1 program, so proof-of-concept and commercial relevance remain uncertain. [#8-K-2026-02-26]
Momentum
57
Value
65
Sentiment
54
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $10.50 · Bull $13.50 · Bear $6.50
Data freshness
Prices
As of 2026-07-22
Fundamentals
As of 2026-07-20 • Vendor: Data Vendor v1
Scores
As of 2026-07-22 • Model: HYBRID_IC_RP
AI Memo
As of 2026-04-28 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-07-22
Investment thesis
As of 2026-07-22
Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net Neutral
Target $21.00
Why
Momentum57 · Δ7d +14.8
Value65 · Δ7d -0.1
Sentiment54 · Δ7d +2.9
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Value · See fundamentals
Momentum
57
26% active weight
Current posture
7d trendSoftening
Δ7d
+14.8
Δ21d
+6.8
Value
65
39% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
-0.2
Sentiment
54
34% active weight
Current posture
7d trendImproving
Δ7d
+2.9
Δ21d
+4.6
Why this grade
Composite grade B. Momentum 56.6 / Value 64.8 / Sentiment 54.4
Fundamentals (TTM)As of 2026-07-20
Fundamentals (TTM)
As of 2026-07-20
Market Cap
$2.32B
Beta
0.83
Shares Out
254.16M
P/E (TTM) · Derived
7.2
P/S (TTM)
2.60
P/FCF (TTM)
47.30
Rev YoY
+7.5%
EPS YoY
-2979600.0%
Gross Margin
+97.5%
Op Margin
+11.5%
Net Debt
$202.38M
Current Ratio
1.91
As of 2026-07-22 • Updated nightlySource: Internal modelMethodology